Imara to Webcast Conference Call of Full Year 2021 Financial Results and Business Highlights
March 08, 2022 07:00 ET
|
Imara, Inc.
BOSTON, March 08, 2022 (GLOBE NEWSWIRE) -- Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients...
Imara to Present at Upcoming Investor Conferences
September 03, 2021 07:00 ET
|
Imara, Inc.
BOSTON, Sept. 03, 2021 (GLOBE NEWSWIRE) -- Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients...
Imara Announces Completion of Patient Enrollment in Ardent Phase 2b Clinical Trial of IMR-687 (tovinontrine) for Sickle Cell Disease
August 05, 2021 07:15 ET
|
Imara, Inc.
BOSTON, Aug. 05, 2021 (GLOBE NEWSWIRE) -- Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients...
Imara to Webcast Conference Call of Second Quarter 2021 Financial Results and Business Highlights
July 30, 2021 07:00 ET
|
Imara, Inc.
BOSTON, July 30, 2021 (GLOBE NEWSWIRE) -- Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients...
Imara Announces Pricing of Public Offering
July 13, 2021 22:58 ET
|
Imara, Inc.
BOSTON, July 13, 2021 (GLOBE NEWSWIRE) -- Imara Inc. (the “Company”) (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to...
Imara Announces Appointment of Laura A. Williams, M.D., MPH to Board of Directors
June 30, 2021 07:00 ET
|
Imara, Inc.
BOSTON, June 30, 2021 (GLOBE NEWSWIRE) -- Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients...
Imara Presents Clinical Data on IMR-687 in Sickle Cell Disease at the European Hematology Association (EHA) Annual Congress
June 11, 2021 03:00 ET
|
Imara, Inc.
Final data from 93-patient Phase 2a clinical trial show lower annualized rate of vaso-occlusive crises (VOCs) and longer time to first VOC on IMR-687 Interim open-label extension clinical trial...
Imara Reports First Quarter 2021 Financial Results and Business Highlights
May 11, 2021 07:00 ET
|
Imara, Inc.
On-track to report interim analyses for both Ardent sickle cell disease and Forte beta-thalassemia Phase 2b clinical trials in the second half of 2021 Completed enrollment in the...
Imara to Webcast Conference Call of First Quarter 2021 Financial Results and Business Highlights
May 04, 2021 07:00 ET
|
Imara, Inc.
BOSTON, May 04, 2021 (GLOBE NEWSWIRE) -- Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients...